anti-EGFR-IL-dox

anti-EGFR-IL-dox is a targeted nanomedicine consisting of pegylated liposomes containing the cytotoxic agent doxorubicin. The liposomal surface is functionalized with Fab' fragments of the anti-EGFR monoclonal antibody cetuximab, allowing for specific targeting of cells expressing the epidermal growth factor receptor (EGFR). Developed by the Swiss Group for Clinical Cancer Research (SAKK) with support from Merrimack Pharmaceuticals, it was primarily investigated as a first-line treatment for advanced triple-negative breast cancer (TNBC). The drug is designed to improve the therapeutic index of doxorubicin by concentrating the drug within EGFR-positive tumor cells through receptor-mediated endocytosis. Although the formulation demonstrated a favorable safety profile and was well-tolerated in clinical trials, it failed to meet primary efficacy endpoints in a multicenter Phase II study (SAKK 24/14) for TNBC, leading to the conclusion that it should not be further developed for this specific indication.

Other names

anti-EGFR immunoliposomes loaded with doxorubicindoxorubicin-loaded anti-EGFR immunoliposomesanti-EGFR-ILs-doxorubicin